DAHANCA 10:达贝泊汀α联合放疗治疗头颈部鳞癌的随机III期试验
该多中心开放标签随机III期试验评估达贝泊汀α纠正低血红蛋白对头颈部鳞癌放疗结局的影响。计划中期分析显示实验组更差后提前终止,共纳入522例,分析513例。达贝泊汀α组5年局部区域失败率47%对34%,HR 1.53,无事件生存、疾病特异性死亡和总生存均更差。结论为放疗期间纠正血红蛋白导致肿瘤控制和生存显著更差。
要点
- 达贝泊汀α纠正血红蛋白至计划值达81%,但实验组5年局部区域失败率47%对34%。
- 实验组无事件生存HR 1.36、疾病特异性死亡HR 1.43、总生存HR 1.30均更差。
- 未观察到心血管事件风险增加或急慢性放疗相关发病率显著差异。
核心结论
- 头颈部鳞癌放疗期间使用达贝泊汀α纠正血红蛋白水平导致肿瘤控制和生存显著更差。
研究设计与样本
- 丹麦头颈癌组开展的多中心、开放标签、随机III期试验,计划入组600例,实际纳入522例,513例可分析(达贝泊汀α组254例,对照组259例)。
- 符合条件者为接受原发放疗且血红蛋白低于14.0 g/dl的患者,随机接受加速分次放疗联合或不联合达贝泊汀α,所有患者均接受缺氧放射增敏剂尼莫拉唑。
- 达贝泊汀α在放疗期间每周给药,直至血红蛋白超过15.5 g/dl;计划中期分析显示实验组更差后试验提前终止。
主要发现
- 达贝泊汀α组81%的患者血红蛋白升至计划值,依从性良好,无过多严重不良事件。
- 实验组未观察到心血管事件风险增加,急性和晚期放疗相关发病率无显著差异。
- 所有单变量分析结果在多变量分析中得到确认。
临床怎么用
- 头颈部鳞癌患者放疗期间不应使用达贝泊汀α纠正低血红蛋白以试图改善肿瘤结局。
局限性
- 试验因计划中期分析显示实验组更差而提前终止,实际入组522例低于计划的600例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate if correction of low hemoglobin (Hb) levels by means of darbepoetin alfa improves the outcomes of radiotherapy in patients with squamous cell carcinoma of the head and neck (HNSCC). PATIENTS AND METHODS: Patients eligible for primary radiotherapy and who had Hb values below 14.0 g/dl were randomized to receive accelerated fractionated radiotherapy with or without darbepoetin alfa. Patients also received the hypoxic radiosensitizer nimorazole. Darbepoetin alfa was given weekly during radiotherapy or until the Hb value exceeded 15.5 g/dl. RESULTS: Following a planned interim analysis which showed inferiority of the experimental treatment the trial was stopped after inclusion of 522 patients (of a planned intake of 600). Of these, 513 were eligible for analysis (254 patients treated with darbepoetin alfa and 259 patients in the control group). Overall, the patients were distributed according to the stratification parameters (gender, T and N staging, tumor site). Treatment with darbepoetin alfa increased the Hb level to the planned value in 81% of the patients. The compliance was good without excess serious adverse events. The results showed a poorer outcome with a 5-year cumulative loco-regional failure rate of 47% vs. 34%, Hazard Ratio (HR): 1.53 [1.16-2.02], for the darbepoetin alfa vs. control arm, respectively. This was also seen for the endpoints of event-free survival (HR: 1.36 [1.09-1.69]), disease-specific death (HR: 1.43 [1.08-1.90]), and overall survival (HR: 1.30 [1.02-1.64]). There was no enhanced risk of cardio-vascular events observed in the experimental arm or any significant differences in acute or late radiation related morbidity. All univariate analyses were confirmed in a multivariate setting. CONCLUSION: Correction of the Hb level with darbepoetin alfa during radiotherapy of patients with HNSCC resulted in a significantly poorer tumor control and survival.
引用
- Overgaard J, Hoff CM, Hansen HS, et al. DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group. Radiother Oncol. 2018. PMID: 29523409. doi:10.1016/j.radonc.2018.02.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。